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A 3-year-old Nigerian boy was treated with phenobarbitone after having a nonfebrile seizure. Two weeks later his urine was
found to contain porphobilinogen, indicating that latent acute intermittent porphyria had been unmasked by phenobarbitone. The
drug was discontinued and carbamazepine was substituted. The urine became free of porphobilinogen and the patient remained
well. In developing countries phenobarbitone is the most widely used anticonvulsant; it must be avoided in acute intermittent
porphyria, and carbamazepine may be tolerated.
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INTRODUCTION
Most people with epilepsy live in developing coun-
tries1 and the great majority receive no treatment2, 3.
Acute intermittent porphyria (AIP) is a rare inherited
disease, and seizures are typically a manifestation of
acute attacks. AIP may also coexist with idiopathic or
symptomatic epilepsy4. Since most antiepileptic drugs
(AEDs) may precipitate attacks of AIP in susceptible
patients, a knowledge of the effects of AEDs is im-
portant. Attempts to treat seizures may unmask AIP
which has previously remained latent.
CASE REPORT
A 3-year-old boy was seen in the Paediatric Neurol-
ogy Clinic of the University of Benin Teaching Hospi-
tal after having an unprovoked nonfebrile generalized
seizure. Patients with a single unprovoked seizure may
benefit from treatments with AEDs5, and in Nigeria a
convulsing young child may be subjected to traditional
practices and medications with serious or even fatal re-
sults6, 7, and so it is considered prudent to attempt to
prevent convulsions, whether febrile or nonfebrile, in
this age group. Phenobarbitone was prescribed, 45 mg
(3 mg kg−1) daily.
At the return visit 2 weeks later to assess control of
seizures and possible side effects of phenobarbitone,
he had remained well, but his mother, who was a nurse,
had noticed that his urine became dark after standing.
The Watson–Schwarz test for porphobilinogen (PBG)
in the urine was strongly positive, and this indicated
that latent AIP had been unmasked by phenobarbitone;
the drug was gradually withdrawn and carbamazepine
100 mg t.d.s. was commenced.
Four weeks later the Watson–Schwarz test was neg-
ative. Carbamazepine was continued for 3 years and
gradually withdrawn. The boy remained well with no
recurrence of seizures during a further year’s follow
up, and always came near the top of his class at school.
There was no history suggestive of AIP in the mother’s
family. The father was a surgeon working in another
part of the country and was not seen at any time.
DISCUSSION
AIP is the most common of the hepatic porphyrias and
results from a deficiency of the enzyme porphobilino-
gen deaminase. It is inherited as an autosomal dom-
inant, and symptomless and symptomatic heterozy-
gotes have 50% deficiency of the enzyme. Approxi-
mately 90% of those who inherit the deficiency remain
clinically unaffected throughout their lives. During a
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crisis the urine may be found to contain PBG, por-
phyrins and the precursor of PBG, δ-amino-laevulinic
acid (ALA)8.
AIP is usually latent before puberty and symptoms
are more frequent in females than in males. Symptoms
may be precipitated by hormonal and nutritional fac-
tors, and by the administration of drugs, probably by
inducing hepatic ALA-synthase. Amongst the drugs
which may do this are most AEDs8.
Hereditary coproporphyria is much less common
and less severe than AIP, but may cause difficulties
in the management of epilepsy in childhood. Dur-
ing a crisis PBG my be found in the urine. In the
present case the faeces were not examined for co-
proporphyrins, so this diagnosis remains a remote
possibility9.
Abdominal pain is almost always present during a
crisis in AIP. Seizures are not infrequent and hyperten-
sion and hyponatraemia may be factors. Inappropriate
secretion of antidiuretic hormone may be responsible
for hyponatraemia.
AIP has been described in West Africa; 1 out of
3 patients who presented with abdominal pain had
seizures10.
Seizures may be the presenting symptom of AIP in
childhood or adult life, in which case the administra-
tion of AEDs may have disastrous consequences. A
man who was thought to have idiopathic seizures was
treated with phenytoin; when his condition worsened
treatment was changed to sodium valproate, but dete-
rioration continued. He was found to have AIP; AEDs
were discontinued, but recovery from motor neuropa-
thy was incomplete11.
Although AIP is usually latent before puberty, 37
cases in children were collected from the literature as
long ago as 197412, though not all were fully docu-
mented. A child described in that report was initially
treated with phenobarbitone and phenytoin. Hyperten-
sion and hyponatraemia developed and it was noticed
that the urine turned dark red after standing. After the
AEDs were withdrawn recovery was complete despite
coma for 3 days.
Cases of AIP in childhood have continued to be re-
ported at intervals13–16, though it may be that the use
of diazepam, which is safe, rather than phenobarbi-
tone, for the emergency treatment of seizures, has re-
sulted in fewer instances of children with latent AIP
developing symptoms of the disease. An alternative
and safe emergency treatment of seizures in AIP is
magnesium sulphate17.
In order to determine the safety of AEDs in AIP, in
vitro test systems have been employed. Chick embryo
hepatocyte cultures were used, and production of por-
phyrins was increased by phenobarbitone, phenytoin,
sodium valproate, carbamazepine and clonazepam, but
not by diazepam or sodium bromide18.
Nevertheless, the results of in vitro drug testing do
not always apply to all patients. Even drugs thought
to be unsafe are not always harmful to patients with
AIP8, as is shown by the tolerance to carbamazepine of
the patient discussed here, and a similar case in a pre-
vious report19. Clonazepam has also been used safely,
at a low dose20.
Concerning long-term use of AEDs for children
with epilepsy and AIP, textbooks of paediatrics of-
fer little or no advice. Bromides are safe, but are not
likely to be tolerated. The modern treatment of choice
is probably with gabapentin or vigabatrin4, 21, which
are not metabolized in the liver. Gabapentin has been
used successfully in the treatment of two patients with
seizures and AIP22.
These newer and safe AEDs are not likely to be
available in developing countries, where phenobar-
bitone is the most widely used drug for epilepsy23,
largely because of its cheapness. Carbamazepine,
though more costly, is available in several countries23,
and has been found to be effective in intractable
epilepsy in children in Nigeria24. It is encouraging to
know that it may be used, with due consideration and
when indicated, in AIP. Monitoring of the urine for
PBG is recommended.
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